SY-5609 is under clinical development by Syros Pharmaceuticals and currently in Phase I for Metastatic Pancreatic Cancer. According to GlobalData, Phase I drugs for Metastatic Pancreatic Cancer have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SY-5609’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SY-5609 is under development for the treatment of triple-negative breast cancer, small cell lung cancer, colorectal cancer, HER2 negative metastatic breast cancer, ovarian cancer, metastatic pancreatic cancer(pancreatic ductal adenocarcinoma), mantle cell lymphoma and other solid tumors. It is administered orally. The drug candidate acts by targeting Cyclin Dependent Kinase 7 (CDK7).
Syros Pharmaceuticals overview
Syros Pharmaceuticals (Syros) is a biopharmaceutical company that develops medicines for the treatment of cancer, immune-mediated diseases, and other diseases. The company offers its pipeline products under clinical trials including Tamibarotene, an oral potent and selective RARa agonist, SY-2101, a arsenic trioxide (ATO) and SY-5609, a highly selective and potent oral inhibitor. Syors products are used to treat the patients with acute myeloid leukemia and myelodysplastic syndrome (MDS); acute promyelocytic leukemia, pancreatic cancer and BRAF-mutant colorectal cancer. It also provides gene regulation, new medicines development, proprietary drug development platform, and integrated gene control assay technologies. The company’s gene control platform identifies novel gene control targets linked to genomically defined patient populations and drugging gene control targets. It partners with other biopharmaceutical companies to extend the potential of our gene control platform across multiple therapeutic areas and diseases. Syros is headquartered in Cambridge, Massachusetts, the US
For a complete picture of SY-5609’s drug-specific PTSR and LoA scores, buy the report here.